全球关节止痛注射市场：市场规模、占有率、成长分析、按类型、按应用划分 - 产业预测，2023-2030 年

Global Joint Pain Injections Market Size, Share, Growth Analysis, By Type(corticosteroids, hyaluronic acid), By Application(osteoarthritis, rheumatoid arthritis) - Industry Forecast 2023-2030

出版日期: 2023年11月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2021年全球关节疼痛注射剂市场规模为63亿美元，从2022年的67.9亿美元增长到2030年的122.8亿美元，预计在预测期内（2023-2030年）将以复合年增长率增长7.7%。

由于关节相关疾病盛行率的增加、老年人口的增加以及对微创替代治疗的需求不断增加等主要因素，全球关节疼痛注射市场正在经历显着增长。关节疼痛注射可以针对性地缓解疼痛并改善关节功能，是手术介入的可行替代方案。该市场的注射技术不断进步，不断开发新产品以提高功效和耐用性。此外，再生医学和生物製药的日益接受度正在对市场形势产生重大影响。儘管有这些积极的趋势，但注射高成本、报销范围有限和潜在副作用等挑战仍然可能阻碍整体市场的成长。

自上而下和自下而上的方法已用于预测和检验关节止痛注射剂的全球市场规模，并预测其他各个相关子市场的市场规模。用于估计市场规模的调查方法包括以下详细资讯：用于确定市场主要企业的二次研究，以及用于确定每个地区的市场占有率的主要和二次研究。整个过程包括研究主要企业的年度和财务报告以及广泛的采访，以获得执行长、副总裁、董事和行销负责人等行业领导者的重要见解。所有占有率比率和细目分类均使用二手资讯确定并使用主要资讯检验。本研究涵盖的所有可能影响市场的参数都经过了考虑、详细研究、初步研究检验和分析，以获得最终的定量和定性资料。

全球关节止痛注射剂细分市场分析

关节疼痛注射剂的全球市场按类型、应用和地区细分。依类型分为皮质类固醇、玻尿酸、富血小板血浆（PRP）、干细胞等。依应用，市场分为骨关节炎、类风湿性关节炎、痛风和其他关节相关疾病。依地区划分，分为北美、欧洲、亚太地区、中东/非洲、拉丁美洲。

全球关节痛注射市场的驱动因素

全球关节疼痛注射市场是由关节相关疾病日益普及所推动的。骨关节炎和类类风湿性关节炎等疾病正在增加，对关节疼痛注射等有效的疼痛管理解决方案产生了巨大的需求。老年人口的增加、久坐的生活方式以及运动相关伤害的增加是促进市场成长的因素。

全球关节止痛注射剂市场的抑制因素

治疗成本高：全球关节疼痛注射剂市场的一个重要抑制因素是与治疗相关的高成本。关节疼痛注射的费用可能会限制保险不足的个人获得治疗的机会，特别是在医疗保健费用令人担忧的地区。此外，某些国家的报销政策和监管障碍是市场成长的潜在障碍。

关节止痛注射剂的全球市场趋势

越来越多地采用微创手术：全球关节疼痛注射市场的一个主要趋势是越来越多地采用微创手术。患者和医疗保健提供者越来越多地选择非手术治疗关节疼痛，推动注射作为治疗选择的普及。微创手术（包括关节止痛注射）具有恢復时间更快、併发症风险更低和术后疼痛更少等优点。这些门诊注射透过直接向受影响的关节给药来提供有针对性的疼痛缓解。这一趋势与对个体化、以患者为中心的护理日益增长的需求相吻合，从而可以根据每位患者的具体需求制定个性化的治疗计划。

执行摘要
调查方法
母市场分析
主要市场考察
- 技术分析
- 价格分析
- 供应链分析
- 价值链分析
- 市场生态系统
- 智慧财产权分析
- 贸易分析
- Start-Ups分析
- 原料分析
- 创新矩阵
- 研发线产品分析
- 总体经济指标
- 主要投资分析
- 关键成功因素
- 竞争程度
市场动态及展望
- 市场动态
  - 促进因素
  - 机会
  - 抑制因素
  - 任务
- 监管形势
- 波特的分析
- 对未来中断的特殊考察
全球关节疼痛注射市场：按类型
- 市场概况
- 皮质类固醇
- 玻尿酸
- 富血小板血浆 (PRP)
- 干细胞
- 其他的
关节疼痛注射剂的全球市场：按应用分类
- 市场概况
- 骨关节炎
- 类风湿性关节炎
- 痛风
- 其他关节相关疾病
全球关节疼痛注射剂市场规模：按地区划分
- 市场概况
- 北美洲
  - 美国
  - 加拿大
- 欧洲
  - 德国
  - 西班牙
  - 法国
  - 英国
  - 其他欧洲国家地区
- 亚太地区
  - 中国
  - 印度
  - 日本
  - 韩国
  - 其他亚太地区
- 拉丁美洲
  - 巴西
  - 其他拉丁美洲地区
- 中东和非洲 (MEA)
  - 海湾合作委员会国家
  - 南非
  - 其他中东/非洲地区
竞争形势
- 前5名企业对比
- 主要企业市场定位（2021年）
- 主要市场参与者所采取的策略
- 关键成功策略
- 近期市集活动
- 主要企业市场占有率（2021年）
主要企业简介
- Johnson & Johnson
- Pfizer Inc.
- Sanofi
- Novartis AG
- Eli Lilly and Company
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Roche Holding AG
- AbbVie Inc.
- AstraZeneca plc
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Celgene Corporation
- Gilead Sciences, Inc.
- Grunenthal GmbH
- Mylan NV
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited

简介目录

Product Code: SQMIG35I2165

Global Joint Pain Injections Market size was valued at USD 6.3 billion in 2021 and is poised to grow from USD 6.79 billion in 2022 to USD 12.28 billion by 2030, growing at a CAGR of 7.7% in the forecast period (2023-2030).

The global market for Joint Pain Injections is undergoing substantial growth driven by key factors such as the increasing prevalence of joint-related disorders, a growing geriatric population, and a rising demand for minimally invasive treatment alternatives. Joint pain injections, offering targeted pain relief and improved joint function, serve as a viable option to surgical interventions. The market is marked by ongoing advancements in injection technologies and the formulation of new products aimed at enhancing efficacy and durability. Furthermore, the increasing acceptance of regenerative medicine and biologic injections is significantly influencing the market landscape. Despite these positive trends, challenges including the high cost of injections, limited reimbursement coverage, and potential side effects pose considerations that may impede the overall growth of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Joint Pain Injections Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global Joint Pain Injections Market Segmental Analysis

The Global Joint Pain Injections Market is segmented by type, application, and region. Based on type, the market can be segmented into include corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), stem cells, and others. Based on application, the market is segmented into osteoarthritis, rheumatoid arthritis, gout, and other joint-related disorders. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Joint Pain Injections Market

The global Joint Pain Injections market is propelled by the increasing prevalence of joint-related disorders. Conditions like osteoarthritis and rheumatoid arthritis are on the rise, creating a substantial demand for effective pain management solutions, notably joint pain injections. Contributing factors include the growing aging population, sedentary lifestyles, and an escalation in sports-related injuries, collectively fostering market growth.

Restraints in the Global Joint Pain Injections Market

High Cost of Treatment: A notable restraint in the global Joint Pain Injections market is the high cost associated with treatment. The expense of joint pain injections, particularly for individuals lacking sufficient insurance coverage, can limit access to these treatments, particularly in regions where healthcare affordability is a concern. Additionally, reimbursement policies and regulatory hurdles in certain countries pose potential obstacles to market growth.

Market Trends of the Global Joint Pain Injections Market

Increasing Adoption of Minimally Invasive Procedures: A significant trend in the global Joint Pain Injections market is the rising adoption of minimally invasive procedures. Patients and healthcare providers are increasingly opting for non-surgical alternatives in managing joint pain, driving the popularity of injections as a treatment option. Minimally invasive procedures, including joint pain injections, offer advantages such as shorter recovery times, reduced risk of complications, and diminished postoperative pain. Administered in outpatient settings, these injections provide targeted pain relief by delivering medications directly to the affected joint. This trend aligns with the growing demand for personalized and patient-centric care, allowing for individualized treatment plans tailored to each patient's specific needs.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
- Regulatory Landscape
- Porters Analysis
  - Competitive rivalry
  - Threat of Substitute Products
  - Bargaining Power of Buyers
  - Threat of New Entrants
  - Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
  - Political Impact
  - Economic Impact
  - Social Impact
  - Technical Impact
  - Environmental Impact
  - Legal Impact
Global Joint Pain Injections Market by Type
- Market Overview
- corticosteroids
- hyaluronic acid
- platelet-rich plasma (PRP)
- stem cells
- and others
Global Joint Pain Injections Market by Application
- Market Overview
- osteoarthritis
- rheumatoid arthritis
- gout
- and other joint-related disorders
Global Joint Pain Injections Market Size by Region
- Market Overview
- North America
  - USA
  - Canada
- Europe
  - Germany
  - Spain
  - France
  - UK
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - South Korea
  - Rest of Asia-Pacific
- Latin America
  - Brazil
  - Rest of Latin America
- Middle East & Africa (MEA)
  - GCC Countries
  - South Africa
  - Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
  - By Development
  - By Company
  - By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Johnson & Johnson (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Pfizer Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Sanofi (France)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Novartis AG (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Eli Lilly and Company (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Merck & Co., Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- GlaxoSmithKline plc (United Kingdom)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Roche Holding AG (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- AbbVie Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- AstraZeneca plc (United Kingdom)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Bayer AG (Germany)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Boehringer Ingelheim International GmbH (Germany)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Bristol-Myers Squibb Company (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Celgene Corporation (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Gilead Sciences, Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Grunenthal GmbH (Germany)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Mylan N.V. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments